Similar articles

• Design of molecules that specifically recognize and cleave apurinic sites in DNA.

  Berthet N, Boudali A, Constant JF, Decout JL, Demeunynck M, Fkyerat A, Garcia J, Laayoun A, Michon P, Lhomme J. Berthet N, et al. J Mol Recognit. 1994 Jun;7(2):99-107. doi: 10.1002/jmr.300070207. J Mol Recognit. 1994. PMID: 7826679 Review.
• DNA-intercalating ligands as anti-cancer drugs: prospects for future design.

  Denny WA. Denny WA. Anticancer Drug Des. 1989 Dec;4(4):241-63. Anticancer Drug Des. 1989. PMID: 2695099 Review.
• Search for DNA repair inhibitors: selective binding of nucleic bases-acridine conjugates to a DNA duplex containing an abasic site.

  Berthet N, Constant JF, Demeunynck M, Michon P, Lhomme J. Berthet N, et al. J Med Chem. 1997 Oct 10;40(21):3346-52. doi: 10.1021/jm970225t. J Med Chem. 1997. PMID: 9341909
• Design and synthesis of DNA-intercalating 9-fluoren-beta-O-glycosides as potential IFN-inducers, and antiviral and cytostatic agents.

  Alcaro S, Arena A, Neri S, Ottanà R, Ortuso F, Pavone B, Vigorita MG. Alcaro S, et al. Bioorg Med Chem. 2004 Apr 1;12(7):1781-91. doi: 10.1016/j.bmc.2003.12.034. Bioorg Med Chem. 2004. PMID: 15028268
• Design, synthesis, DNA sequence preferential alkylation and biological evaluation of N-mustard derivatives of distamycin and netropsin analogues.

  Xie G, Gupta R, Lown JW. Xie G, et al. Anticancer Drug Des. 1995 Jul;10(5):389-409. Anticancer Drug Des. 1995. PMID: 7639929